Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperpl...( -- New product now available in ...),Health

-- New product, now available in pharmacies, will provide rapid symptom relief for number one reason men visit a urologist --

CORONA, Calif., April 7 /PRNewswire-FirstCall/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that RAPAFLO(TM) (silodosin), the company's new, uniquely selective alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), is available for patients by prescription. Watson received U.S. Food and Drug Administration (FDA) approval for RAPAFLO(TM) in October 2008.

In clinical trials, RAPAFLO(TM) was proven to rapidly increase urine flow in just two to six hours following the initial dose. In addition, noticeable relief of BPH symptoms was realized in just three to four days, with the majority of patients, including men on concomitant cardiovascular medications, achieving at least a three-point improvement in IPSS score, regardless of age or severity of symptoms. RAPAFLO(TM) is associated with a low incidence of orthostatic hypotension and the associated symptoms of syncope, fainting and dizziness.

"The launch of RAPAFLO(TM) is an important milestone and, coupled with the forthcoming launch of GELNIQUE, marks the continued strength and expansion of Watson's Brand Division and urology franchise," said Paul Bisaro, President and Chief Executive Officer of Watson. "We are confident that the proven rapid efficacy and safety of RAPAFLO(TM) will provide BPH patients and their physicians an important treatment option. We expect our 3-day sample packs to clearly demonstrate the rapid relief and tolerability of RAPAFLO(TM)."

The product label provides that one 8 mg RAPAFLO(TM) capsule be taken once daily with a meal. Stocking efforts have ensured the product
'/>"/>